Improving the efficacy of DC vaccines - ArcelisTM

Argos has developed a novel DC maturation method that dramatically improves DC immunopotency as assessed by in vitro assays compared to DCs matured using the common ‘cytokine cocktail’ method. This new maturation protocol involves transfecting CD40L-encoding RNA along with the tumor RNA payload after maturation with TNF-alpha, IFN-gamma, and PGE2. DC prepared by this method secrete large amounts of IL-12 and no IL-10. This DC platform is now known as ArcelisTM.

• biomaterial type
• CD40 ligand,
• Interleukin-10,
• Interleukin-12 cytokine

created over 16 years ago (2 March 2009)    last modified over 13 years ago (28 September 2011)   [ RDF ]   [ RelFinder ]